PT-141 (Bremelanotide): The Peptide That Reignites Sexual Desire

Low libido is one of the most common — and most under-discussed — sexual health complaints among adults. It affects men and women across all age groups, though it becomes increasingly prevalent with age, hormonal changes, stress, and relationship dynamics. The challenge is that most well-known sexual health medications address the mechanics of sex (blood flow, erection quality) but not the desire to have it in the first place.

PT-141, also known by its pharmaceutical name bremelanotide, takes a fundamentally different approach. Rather than working on blood vessels, it works on the brain — specifically the neural circuits that generate sexual motivation. The result is an increase in genuine sexual desire, not just improved physical function.

What Is PT-141 (Bremelanotide)?

PT-141 is a synthetic peptide derived from alpha-melanocyte-stimulating hormone (α-MSH). Its development began as a potential sunless tanning agent — researchers noted that participants in early trials reported an unexpected side effect: spontaneous sexual arousal. That observation led to decades of clinical investigation into its sexual function applications.

Bremelanotide was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of only two FDA-approved medications for low libido in women. It is also used off-label in men to address low sexual desire.

How PT-141 Works: The Brain Mechanism

PT-141 activates melanocortin receptors in the brain — specifically MC3R and MC4R receptors located in the hypothalamus and limbic system. These receptors are involved in regulating sexual behavior, appetite, and reward pathways.

When PT-141 binds to these receptors, it triggers a cascade of neurochemical activity — increasing dopamine signaling in regions associated with motivation and reward. The subjective effect is an increase in sexual desire, arousal, and receptivity. Importantly, this mechanism is centrally mediated (brain-based) rather than peripherally mediated (blood-flow-based), which is what makes it categorically different from medications like sildenafil or tadalafil.

PT-141 vs. PDE5 Inhibitors (Viagra/Cialis): A Key Distinction

This distinction matters clinically:

• Sildenafil (Viagra) and tadalafil (Cialis) — PDE5 inhibitors — work by relaxing smooth muscle in blood vessels, increasing blood flow to the genitals. They are highly effective for erectile dysfunction but do not increase libido or sexual desire. If a man has no desire to have sex, sildenafil won't create it.
• PT-141 (Bremelanotide) works on the brain's desire centers. It doesn't directly affect blood vessels or genital blood flow. Instead, it increases the psychological and neurological experience of wanting sex.

For men and women where the primary issue is low sexual desire rather than mechanical dysfunction, PT-141 addresses the actual root cause. Some patients and physicians use both — PT-141 for desire and a PDE5 inhibitor for performance — in combination.

PT-141 for Men: Off-Label Use and Evidence

While PT-141 is FDA-approved only for women (as Vyleesi for HSDD), it has been used off-label in men for years. Clinical trials have examined bremelanotide in men with both psychogenic and organic erectile dysfunction, with results showing:

• Increased sexual desire and arousal
• Improved erectile function (likely through central dopaminergic mechanisms)
• Benefit in men who had not responded adequately to sildenafil

A notable 2004 clinical trial published in the International Journal of Impotence Research found that bremelanotide produced erections in 80% of men with erectile dysfunction, including those who did not respond to Viagra. While this was an early-phase trial, the results underscored the value of central versus peripheral mechanisms in treating sexual dysfunction.

PT-141 for Women: FDA-Approved Treatment

Hypoactive sexual desire disorder (HSDD) — defined as persistently low sexual desire that causes significant personal distress — affects an estimated 10% of premenopausal women. Vyleesi (bremelanotide) was FDA-approved specifically for this indication after demonstrating statistically significant improvements in desire and distress in large Phase 3 clinical trials.

In the RECONNECT trials, women using Vyleesi reported:

• Significantly more satisfying sexual events compared to placebo
• Reduced personal distress related to low sexual desire
• Improved scores on validated sexual function questionnaires

How PT-141 Is Administered

PT-141 is administered as a subcutaneous injection — typically into the abdomen or thigh — approximately 45 minutes to 1 hour before anticipated sexual activity. The FDA-approved Vyleesi auto-injector is designed for self-administration and is straightforward to use.

Compounded PT-141 from licensed compounding pharmacies is also available via telehealth prescription, typically at lower cost than brand-name Vyleesi. It comes as a lyophilized powder reconstituted with bacteriostatic water, drawn into an insulin syringe, and self-injected subcutaneously.

Typical Dosing

• FDA-approved dose (Vyleesi): 1.75 mg subcutaneous, 45 minutes before sexual activity. Maximum one dose per 24 hours and no more than one dose per week.
• Compounded/off-label doses: Often 0.5–2 mg depending on individual tolerance and response, typically starting low and titrating.

Side Effects of PT-141

PT-141 is generally well-tolerated, but side effects do occur. The most common include:

• Nausea — the most frequently reported side effect, typically mild to moderate and short-lived. Occurs in up to 40% of users in clinical trials but rarely causes discontinuation.
• Flushing — warmth or redness in the face and neck, usually mild
• Headache
• Transient blood pressure changes — usually modest and short-lived; PT-141 may transiently increase blood pressure. Patients with cardiovascular disease or on antihypertensive medications should discuss this with their physician.
• Injection site reactions — mild soreness or redness at the injection site
• Hyperpigmentation — with repeated use, some patients experience darkening of the face, gums, or breast area related to melanocortin receptor activation

Pre-treatment with an antiemetic (anti-nausea medication) can significantly reduce nausea. Many patients find that nausea diminishes with subsequent uses as they learn their optimal dose.

Who Is a Good Candidate for PT-141?

PT-141 may be appropriate for:

• Premenopausal women with HSDD (hypoactive sexual desire disorder)
• Postmenopausal women with low libido (off-label)
• Men with low sexual desire who haven't responded fully to testosterone or PDE5 inhibitors
• Men or women who want to address desire specifically rather than physical function
• Patients looking for an as-needed (situational) option rather than daily medication

PT-141 is not appropriate for patients with cardiovascular disease, uncontrolled hypertension, or a history of hypersensitivity to bremelanotide.

Getting PT-141 Through Telehealth

Obtaining PT-141 through traditional healthcare pathways often means navigating referrals and specialists. Through telehealth, the process is significantly faster and more private. A licensed physician reviews your health history, discusses your symptoms, and — if appropriate — writes a prescription that's sent to a compounding pharmacy. The medication arrives at your door.

Visit our sexual health page to learn more about Truventa's approach to treating low libido in men and women. For men interested in addressing both desire and performance, you may also want to explore our articles on low testosterone treatment and our broader TRT program.

For other peptide therapies that support overall well-being and longevity, see our peptides program and our guide to glutathione benefits.

The Bottom Line

PT-141 (bremelanotide) is a clinically proven peptide that increases sexual desire by acting on the brain's melanocortin system — a fundamentally different mechanism than ED medications that address blood flow. It's FDA-approved for HSDD in women and used off-label in men with promising results. As an as-needed, subcutaneous injection taken before sexual activity, it offers a targeted, non-hormonal option for addressing low libido at its neurological source.

If low sexual desire is affecting your quality of life, PT-141 is worth discussing with a knowledgeable telehealth provider who can assess whether it's right for your specific situation.